Search results | bayer

Reports

Partnering Agreements with Bayer

This report provides all the information you require to better understand Bayer and its partnering interests and activities over the past seven years.

Insights

Bayer hungry for pharma deals to expand business

Big pharma company Bayer , is going hunting for pharma deals again, with its chief executive expected to tell media outlets  that it is looking for further takeover pharma deals. 

Equity firms eye Bayer’s plastic business merger

Private equity firms are circling Bayer’s €10bn plastics business merger, hoping to divert the German drugmaker from its plan to list the division, two people familiar with the matter said yesterday.

Bayer Healthcare

Bayer is a top pharmaceutical company based in Leverkusen, Germany

Bayer also wants to swap business units with Merck

Bayer is offering to swap its animal health assets for Merck & Co Inc’s consumer healthcare business, people familiar with the matter said on Tuesday, in a move that could give the German drugmaker a leg up in the $14 billion auction of the Merck business.

Bayer offers $2.4 billion for Algeta

Bayer  has proposed to pay $2.4 billion for Norway’s Algeta, its partner for a new prostate cancer treatment, at a 27 percent premium to the stock’s last close, Algeta said on Tuesday.

Partnering with Bayer: Partners for innovation and success

Bayer is a top pharma company active in partnering, licensing and M&A in pharmaceuticals, agricultural and material sciences

Bayer: M&A activity 2005-2013

Bayer has announced 5 M&A deals since 2005, with the lead deals being the acquisition of Schiff Nutrition and AgraQuest

Bayer: Partnering activity 2005-2013

Bayer announced over 190 partnering / licensing deals since 2005, with 23 deals in 2012 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in oncology, cardiovascular, hematology, infectives, central nervous system, gynecology and metabolic diseases

Bayer: Company profile

Bayer,  a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Sanofi’s potential acquisition of Bayers diabetes unit tops bio news headlines

The biggest bio news hovering the pharmaceutical market is Bayer‘s much rumored sale of its blood glucose meter business to French healthcare company Sanofi SA

Events

Sorry, your search returned no results.


Deals

Bayer pharma partners with Kyoto University for novel medical treatments

Bayer HealthCare and Kyoto University’s Office of Society-Academia Collaboration for Innovation pharma partners by signing a two-year agreement to jointly identify candidates for possible collaborative research projects.

MetaSysX signs a pharma deal with Bayer

MetaSysX announce the closure of a pharma deal with Bayer CropScience for the coming three years to apply its metabolomics technologies for improving agricultural productivity.

Big pharma, Bayer signs a spins off its plastics unit

Big pharma Bayer will spin off its plastics unit as the company moves further toward focusing solely on the life sciences market.

Quantum Materials acquires patents from Bayer Technology services

Quantum Materials acquires  five diverse sets of patent families from Bayer Technology Services.

Big Pharma, Bayer donates $100,000 to Red Cross

Big pharma, Bayer announced a $100,000 donation to the American Red Cross to support the organization’s national disaster and emergency preparedness efforts across the United States.

Big Pharma, Bayer has awarded $50,000 to NY police commissioner

Big Pharma, Bayer presented New York City Police Commissioner William J. Bratton with a $50,000 donation to the Police Athletic League of New York City in support of its STEM (science, technology, engineering and mathematics) educational programs.

Dimension and Bayer has signed a pharma deal

Dimension Therapeutics announced it has entered into a pharma deal with Bayer HealthCare for the development and commercialization of a novel gene therapy for the treatment of hemophilia A.

Boston Scientific acquires Bayer’s Interventionals Division

Boston Scientific has entered into a definitive agreement to acquire the Interventional Division of Bayer for $415 million in cash, including fees for transitional services.

Bayer and Merck sign a pharma deal for $2.1 billion

Bayer and Merck & Co also agreed to enter into a strategic pharma deal collaboration in the area of cardiovascular diseases with a focus on sGC modulation.

Bayer has finally acquired Merck’s consumer care business

Bayer has agreed to acquire the consumer care business of U.S. pharmaceutical company Merck & Co for a purchase price of USD 14.2 billion (EUR 10.4 billion).

cpbannerad300x150new3gif
biotech-china-300x150jpg
fdagif
RSS Feed Linked In Twitter

Latest Tweets

cpbannerad300x150new2gif
biotech-china-300x150jpg
fdagif